• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Gilead Sciences acquires Calistoga Pharmaceuticals

Gilead Sciences acquires Calistoga Pharmaceuticals

March 1, 2011
CenterWatch Staff

Gilead Sciences made its third major acquisition in the past eight months, buying privately held Calistoga Pharmaceuticals of Seattle for $375 million cash and $225 million in potential milestones.

Foster City, Calif.-based Gilead, which ended 2010 with $5.3 billion in cash, has made a series of acquisitions to diversify its portfolio by getting into oncology and inflammation treatments ahead of patent expirations for its HIV drugs, according to BioWorld Week. In December 2010, it bought privately held Arresto Biosciences for $225 million in cash plus milestones for its lead candidate AB0024 in phase I testing in solid tumors and idiopathic pulmonary fibrosis. Six months earlier Gilead added an early-stage kinase program by acquiring Branford, Conn.-based CGI Pharmaceuticals in a potential $120 million deal, including milestones.

The key to the Calistoga deal is lead candidate CAL-101, which targets phosphoinositide-3 kinase (PI3K) delta isoform and is in phase II studies as a single agent in patients with refractory indolent non-Hodgkin’s lymphoma (iNHL) and in combination with rituximab in treatment-naïve elderly patients with chronic lymphocytic leukemia (CLL).

The deal follows encouraging fourth-quarter and full-year 2010 results for Gilead that met or exceeded expectations. They included full-year product sales of $7.39 billion, up 14% over 2009, full-year total revenues of $7.95 billion, up 13%, and full-year non-GAAP earnings per share of $3.69, up 21%. The company reported product sales for the fourth quarter increased 7% to $1.93 billion from a year ago.

 

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing